



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Standring, David *et al.*

Confirmation No. 2664

Serial No.: 10/662,641

Art Unit :1623

Filed: September 15, 2003

For: β -L-2'-Deoxy-Nucleosides for the Treatment of Resistant HBV Strains and Combination Therapies

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

A Statement Containing Sequence Listing

Dear Sir:


The content of the sequence listing information in computer readable form is identical to the written sequence listing provided herewith, and includes no new matter.

Applicants enclose a written Sequence Listing and a computer readable copy of the Sequence Listing. The computer readable copy of the Sequence Listing is named "Sequence Listing" and is on the enclosed 1.44 MB IBM diskette.

I hereby state that the information recorded in computer readable form is identical to the written Sequence Listing.

I hereby state that the submission, filed in accordance with 37 CFR § 1.821(g), herein does not include new matter.

Respectfully submitted,



Brent R. Bellows
Registration No. 54,709